{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:47:24Z","timestamp":1761742044697},"reference-count":52,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2003,8,5]],"date-time":"2003-08-05T00:00:00Z","timestamp":1060041600000},"content-version":"vor","delay-in-days":1587,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vet Pharm &amp; Therapeutics"],"published-print":{"date-parts":[[1999,4]]},"abstract":"<jats:p>Cimetidine (CIM) is an H<jats:sub>2<\/jats:sub>\u2010receptor antagonist that has been used in racehorses in an attempt to reduce the occurrence of stress\u2010related gastric ulceration. It has also been shown to produce several useful effects other than its gastric acid suppression properties. Further, it is a well documented antagonist of cytochrome P\u2010450 (CYP) mediated oxygenation reactions. Nitric oxide (NO), a recently discovered mediator or modifier of numerous physiological functions, is generated by several forms of nitric oxide synthase (NOS), one of which is inducible (iNOS). Inducible NOS, expressed in neutrophils and macrophages as part of the inflammatory response to noxious stimuli, contains both a CYP and a CYP reductase domain. Because of the similarity of structure of iNOS and CYP, it was decided to determine whether CIM could reduce NO production, using a carrageenan inflammation model in the horse.<\/jats:p><jats:p>\u2003Two experiments were conducted. In Trial 1, six female Thoroughbred horses each had three tissue chambers inserted subcutaneously on the sides of the neck. The study was divided into three treatments: 0.9% NaCl (NaCl), CIM (3 mg\/kg), and aminoguanidine (AG; 25 mg\/kg), an inhibitor of iNOS. Each mare received three i.v. injections 12 h apart prior to instillation of 1 mL of carrageenan into the test chamber. Blood and tissue chamber fluid (TCF) were collected serially. Concentrations of NO<jats:sub>3<\/jats:sub><jats:sup>\u2212<\/jats:sup> (the major metabolite of NO), albumin, total protein, CIM and AG were measured and complete cell counts and differentials were conducted. Trial 2 also used six female Thoroughbred horses implanted with at least two tissue chambers inserted subcutaneously on the sides of the neck. The study was divided into two treatments: NaCl (0.9%) and CIM (6 mg\/kg). Each mare received seven i.v. injections of either NaCl or CIM 8 h apart prior to instillation of 1 mL of carrageenan into the test chamber. Blood and TCF were collected serially as before, and analysed for NO<jats:sub>3<\/jats:sub><jats:sup>\u2212<\/jats:sup> and CIM content. Areas under the curve (<jats:italic>AUC<\/jats:italic>) of the different parameters were calculated for the periods of \u20131\u20131, \u20131\u20133 and \u20131\u20137 days (Trial 1) and \u20132\u20131 for Trial 2. Absolute values were also compared at 4, 8 and 12 h postcarrageenan. Saline treatment did not reduce the elevated concentrations of NO<jats:sub>3<\/jats:sub><jats:sup>\u2212<\/jats:sup> in either plasma or TCF. Plasma, test chamber and control chamber NO<jats:sub>3<\/jats:sub><jats:sup>\u2212<\/jats:sup> concentrations rose from 0 to 12 h, and were very similar in all three sampled fluids. Cimetidine significantly (<jats:italic>P<\/jats:italic> 0.05) decreased NO<jats:sub>3<\/jats:sub><jats:sup>\u2212<\/jats:sup> production in plasma over the periods of \u20131\u20131, \u20131\u20133, and \u20131\u20137 days post inflammation when compared to NaCl treatment in Trial 1. Aminoguanidine and CIM decreased NO<jats:sub>3<\/jats:sub><jats:sup>\u2212<\/jats:sup> production in TCF for the periods \u20131\u20131, 1\u20133, and \u20131\u20137 days post inflammation in Trial 1 and \u20132\u20131 for Trial 2. Both CIM and AG also significantly reduced NO<jats:sub>3<\/jats:sub><jats:sup>\u2212<\/jats:sup> concentrations in plasma and TCF at 12 h postinitiation (Trials 1 and 2). Thus CIM, at the doses studied, was capable of reducing NO<jats:sub>3<\/jats:sub><jats:sup>\u2212<\/jats:sup> concentrations in this model as effectively as AG, a relatively specific inhibitor of iNOS activity.<\/jats:p>","DOI":"10.1046\/j.1365-2885.1999.00196.x","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T10:09:26Z","timestamp":1027678166000},"page":"136-147","source":"Crossref","is-referenced-by-count":11,"title":["Cimetidine inhibits nitric oxide associated nitrate production in a soft\u2010tissue inflammation model in the horse"],"prefix":"10.1111","volume":"22","author":[{"family":"R.P. Hunter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"C.R. Short","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"J.R. McClure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"C.E Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"M.L. Keowen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"J.L. VanSteenhouse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"A.A. Dees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,8,5]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/173.4.971"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(82)90234-5"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(83)90003-1"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.1991.tb00805.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(78)90758-8"},{"key":"e_1_2_6_7_1","doi-asserted-by":"crossref","first-page":"25062","DOI":"10.1016\/S0021-9258(17)31498-9","article-title":"Cysteine 184 of endothelial nitric oxide synthase is involved in heme coordination and catalytic activity.","volume":"269","author":"Chen P.\u2010F.","year":"1994","journal-title":"Journal of Biological Chemistry"},{"key":"e_1_2_6_8_1","doi-asserted-by":"crossref","first-page":"552","DOI":"10.2337\/diab.41.4.552","article-title":"Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction.","volume":"41","author":"Corbett J.A.","year":"1992","journal-title":"Diabetes"},{"key":"e_1_2_6_9_1","first-page":"262","author":"Daniel W.W.","year":"1990","journal-title":"Applied Nonparametric Statistics"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-3278(96)90053-8"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0272-6386(95)90103-5"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.35.040195.001121"},{"key":"e_1_2_6_13_1","first-page":"445","author":"Gibaldi M.","year":"1982","journal-title":"Pharmacokinetics"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(95)02181-H"},{"key":"e_1_2_6_15_1","first-page":"185","article-title":"Inhibitors of nitric oxide synthases.","author":"Griffith G.W.","year":"1996","journal-title":"Methods in Nitric Oxide Research"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.ph.57.030195.003423"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.152.5.7582301"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1993.tb13907.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(90)91245-N"},{"key":"e_1_2_6_20_1","first-page":"55","article-title":"The chemistry of cytochrome P450 reactions.","author":"Guengerich F.P.","year":"1996","journal-title":"Cytochromes P450 Metabolic and Toxicological Aspects."},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.1996.tb00007.x"},{"key":"e_1_2_6_22_1","first-page":"315","author":"Guyton A.C.","year":"1996","journal-title":"Textbook of Medical Physiology"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2432665"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(88)80015-9"},{"key":"e_1_2_6_25_1","first-page":"370","article-title":"A nitric oxide synthase inhibitor reduces inflammation, down\u2010regulates inflammatory cytokines and enhances interleukin\u201010 production in carrageenin\u2010induced oedema in mice.","volume":"82","author":"Ianaro A.","year":"1994","journal-title":"Immunology"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1993.2447"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0003-9861(86)90596-5"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.18.6369"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.66.6.1561"},{"key":"e_1_2_6_30_1","first-page":"47","article-title":"Metabolic fate of nitric oxide and related N\u2010oxides.","author":"Kelm M.","year":"1996","journal-title":"Methods in Nitric Oxide Research"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(95)02225-8"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1006\/niox.1996.0112"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(94)00637-M"},{"key":"e_1_2_6_34_1","first-page":"126","article-title":"Statistical methods for measuring and comparing treatment efficacies: applications to nude mice experimentation.","volume":"48","author":"Lesser M.L.","year":"1980","journal-title":"Experimental Cell Biology"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi00424a003"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi00011a025"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(93)90357-N"},{"key":"e_1_2_6_38_1","first-page":"2002","article-title":"The L\u2010arginine\u2010nitric oxide pathway.","volume":"27","author":"Moncada S","year":"1993","journal-title":"The New England Journal of Medicine"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1990.tb14717.x"},{"key":"e_1_2_6_40_1","first-page":"39","article-title":"The physiology of nitrate uptake.","author":"Pilbeam D.J.","year":"1990","journal-title":"Nitrogen in Higher Plants"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03189641"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.3109\/08923979009006468"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118035"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.15.7240"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2885.1997.00083.x"},{"key":"e_1_2_6_46_1","first-page":"941","article-title":"Nitrite and nitrate pharmacokinetics in the dog, sheep, and pony.","volume":"36","author":"Schneider N.R.","year":"1975","journal-title":"American Journal of Veterinary Research"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-3306.1990.tb04206.x"},{"key":"e_1_2_6_48_1","author":"Stiles W.R.","year":"1990","journal-title":"Formulary of the Texas A & M University Texas Veterinary Medical Center Veterinary Teaching Hospital"},{"key":"e_1_2_6_49_1","first-page":"667","article-title":"Histamine leukocytosis. I. Effect of histamine on peripheral leukocyte counts.","volume":"14","author":"Tasaka K.","year":"1992","journal-title":"Methods and Findings in Experimental Clinical Pharmacology"},{"key":"e_1_2_6_50_1","first-page":"1295","article-title":"The nitric oxide synthase inhibitor, L\u2010N\n                  G\u2010monomethylarginine, reduces carrageenan\u2010induced pleurisy in the rat.","volume":"273","author":"Tracey W.R.","year":"1995","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.174.1.281"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1992.tb14365.x"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi00144a001"}],"container-title":["Journal of Veterinary Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2885.1999.00196.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2885.1999.00196.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T14:22:51Z","timestamp":1698502971000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2885.1999.00196.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,4]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1999,4]]}},"alternative-id":["10.1046\/j.1365-2885.1999.00196.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2885.1999.00196.x","archive":["Portico"],"relation":{},"ISSN":["0140-7783","1365-2885"],"issn-type":[{"value":"0140-7783","type":"print"},{"value":"1365-2885","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,4]]}}}